Literature DB >> 11095880

Healthcare Economics in HIV.

.   

Abstract

In an era of cost-consciousness in the delivery of medical care, the economics of healthcare delivery for HIV-infected persons has been an area of active interest. Interested parties include the payors of HIV care, particularly public insurers, who are paying for an increasing amount of the overall cost of HIV care in the US; providers of care, many of whom are finding it increasingly difficult to provide HIV care in a capitated market; and those persons who are HIV-infected and increasingly caught in the economic turmoil of the HIV healthcare marketplace. This paper will review the literature published over the past year regarding the economics of healthcare for HIV in the US.

Entities:  

Year:  2000        PMID: 11095880     DOI: 10.1007/s11908-000-0018-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  21 in total

1.  Paying for HIV/AIDS care at the turn of the century.

Authors:  J F O'Neill
Journal:  Am J Manag Care       Date:  1999-11       Impact factor: 2.229

2.  Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

Authors:  J Cook; E Dasbach; P Coplan; L Markson; D Yin; A Meibohm; B Y Nguyen; J Chodakewitz; J Mellors
Journal:  AIDS Res Hum Retroviruses       Date:  1999-04-10       Impact factor: 2.205

3.  Impact of combination therapy for HIV infection on inpatient census.

Authors:  R A Torres; M Barr
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

4.  The economic costs of caring for people with HIV infection and AIDS in England and Wales.

Authors:  S Petrou; M Dooley; L Whitaker; E Beck; E Kupek; J Wadsworth; D Miller; A Renton
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

5.  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study.

Authors:  M F Shapiro; S C Morton; D F McCaffrey; J W Senterfitt; J A Fleishman; J F Perlman; L A Athey; J W Keesey; D P Goldman; S H Berry; S A Bozzette
Journal:  JAMA       Date:  1999 Jun 23-30       Impact factor: 56.272

6.  Developing a managed care delivery system for people with HIV/AIDS.

Authors:  B Singer; S Gamliel; R Conviser
Journal:  Am J Manag Care       Date:  1999-11       Impact factor: 2.229

7.  Costs of HIV medical care in the era of highly active antiretroviral therapy.

Authors:  K A Gebo; R E Chaisson; J G Folkemer; J G Bartlett; R D Moore
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

8.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

9.  Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland.

Authors:  R D Moore; R E Chaisson
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-03-01

10.  One world, one hope: the cost of providing antiretroviral therapy to all nations.

Authors:  R S Hogg; A E Weber; K J Craib; A H Anis; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  AIDS       Date:  1998-11-12       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.